Persistence of warfarin therapy for residents in long-term care who have atrial fibrillation

Clinical Therapeutics

Volumn 35, Issue 11, 2013, Pages 1794-1804

  Patel, Aarti A ^a   Reardon, Gregory ^b,c   Nelson, Winnie W ^a   Philpot, Tommy ^d   Neidecker, Marjorie V ^b,e  

^a JANSSEN RESEARCH AND DEVELOPMENT   (United States)

^b Informagenics LLC   (United States)

^c UNIVERSITY OF FINDLAY   (United States)

^d Profiles and Interventions Inc   (United States)

^e OHIO STATE UNIVERSITY   (United States)

Author keywords

anticoagulation; atrial fibrillation; long term care; persistence; warfarin

Indexed keywords

WARFARIN;

AGED; ANTICOAGULANT THERAPY; ARTICLE; CEREBROVASCULAR ACCIDENT; CHRONIC DRUG ADMINISTRATION; DRUG WITHDRAWAL; FEMALE; HEART ATRIUM FIBRILLATION; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; RESIDENTIAL CARE; RETROSPECTIVE STUDY; SURVIVAL;

ANTICOAGULATION; ATRIAL FIBRILLATION; LONG-TERM CARE; PERSISTENCE; WARFARIN;

AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ATRIAL FIBRILLATION; DATABASES, FACTUAL; FEMALE; HUMANS; LONG-TERM CARE; LONGITUDINAL STUDIES; MALE; MULTIVARIATE ANALYSIS; NURSING HOMES; PROPORTIONAL HAZARDS MODELS; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES; STROKE; TREATMENT OUTCOME; WARFARIN;

EID: 84887990967     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2013.09.010     Document Type: Article

References (39)

1. A.S. Go, E.M. Hylek, and K.A. Phillips Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study JAMA 285 2001 2370 2375
2. V.L. Roger, A.S. Go, and D.M. Lloyd-Jones Heart disease and stroke statistics - 2011 update: a report from the American Heart Association Circulation 123 2011 e18 e209
3. C. Marini, F. De Santis, and S. Sacco Contribution of atrial fibrillation to incidence and outcome of ischemic stroke: results from a population-based study Stroke 36 2005 1115 1119
4. P.S. Miller, F.L. Andersson, and L. Kalra Are cost benefits of anticoagulation for stroke prevention in atrial fibrillation underestimated? Stroke 36 2005 360 366
5. P.A. Heidenreich, J.G. Trogdon, and O.A. Khavjou Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association Circulation 123 2011 933 944
6. National Institute of Neurological Disorders and Stroke. Brain basics: preventing stroke. http://www.ninds.nih.gov/disorders/stroke/preventing
7. G. Reardon, W.W. Nelson, and A.A. Patel Prevalence of atrial fibrillation in US nursing homes: results from the National Nursing Home Survey, 1985-2004 J Am Med Dir Assoc 13 2012 529 534
8. European Atrial Fibrillation Trial. Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. EAFT (European Atrial Fibrillation Trial) Study Group Lancet 342 1993 1255 1262
9. M.D. Ezekowitz, and J.A. Levine Preventing stroke in patients with atrial fibrillation JAMA 281 1999 1830 1835
10. V. Fuster, L.E. Ryden, and D.S. Cannom 2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Circulation 123 2011 e269 e367
11. V. Fuster, L.E. Ryden, and D.S. Cannom ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society Circulation 114 2006 e257 e354
12. J.J. You, D.E. Singer, and P.A. Howard Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines Chest 141 Suppl 2012 e531S e575S
13. A.J. Camm, P. Kirchhof, and G.Y. Lip Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC) Eur Heart J 31 2010 2369 2429
14. G.Y. Lip, R. Nieuwlaat, and R. Pisters Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on Atrial Fibrillation Chest 137 2010 263 272
15. American Medical Directors Association. Clinical practice guideline: stroke management and prevention (revised 2011). http://amda.networkats.com/ members-online/members/viewitem.asp?item=CPG20R&catalog=CPGS&pn= 1&af=AMDA. Accessed February 3, 2012.
16. S. Goto, D.L. Bhatt, and J. Rother Prevalence, clinical profile, and cardiovascular outcomes of atrial fibrillation patients with atherothrombosis Am Heart J 156 2008 855 863 863.e2
17. B.J. Quilliam, and K.L. Lapane Clinical correlates and drug treatment of residents with stroke in long-term care Stroke 32 2001 1385 1393
18. M.C. Fang, A.S. Go, and Y. Chang Warfarin discontinuation after starting warfarin for atrial fibrillation Circ Cardiovasc Qual Outcomes 3 2010 624 631
19. T.M. Brown, K. Siu, and D. Walker Development of a conceptual model of adherence to oral anticoagulants to reduce risk of stroke in patients with atrial fibrillation J Manag Care Pharm 18 2012 351 362
20. C.D. Bushnell, L.O. Zimmer, and W. Pan AVAIL Investigators. Persistence with stroke prevention medications 3 months after hospitalization Arch Neurol 67 2010 1456 1463
21. P.P. Kneeland, and M.C. Fang Current issues in patient adherence and persistence: focus on anticoagulants for the treatment and prevention of thromboembolism Patient Prefer Adherence 4 2010 51 60
22. A.B. Platt, A.R. Localio, and C.M. Brensinger Can we predict daily adherence to warfarin?: Results from the International Normalized Ratio Adherence and Genetics (N-RANGE) study Chest 137 2010 883 889
23. A.L. Jorgensen, D.A. Hughes, and A. Hanson Adherence variability in warfarin dose requirements: assessment in a prospective cohort Pharmacoeconomics 14 2013 151 163
24. S.E. Kimmel, Z. Chen, and M. Price The influence of patient adherence on anticoagulation control with warfarin. Results from the International Normalized Ratio Adherence and Genetics (IN-RANGE) study Arch Intern Med 167 2007 229 235
25. G. Reardon, A.A. Patel, and W.W. Nelson Usage of medications with high potential to interact with warfarin among atrial fibrillation residents in long-term care facilities Expert Opin Pharmacother 14 2013 165 173
26. G. Reardon, W.W. Nelson, and A.A. Patel Warfarin for prevention of thrombosis among long-term care residents with atrial fibrillation: evidence of continuing low use despite consideration of stroke and bleeding risk Drugs Aging 30 2013 417 428
27. Medicare Program. Changes to the Medicare Advantage and the Medicare Prescription Drug Benefit Programs for Contract Year 2012 and Other Changes; Final rule. 76 Federal Register 73 (15 April 2011): 21432-21480
28. G. Reardon, N. Pandya, and E.A. Nutescu Use of warfarin therapy among residents who developed venous thromboembolism in the nursing home Am J Geriatr Pharmacother 10 2012 361 372
29. G.I. Carpenter, C. Hastie, and J. Morris Measuring change in activities of daily living in nursing home residents with moderate to severe cognitive impairment BMC Geriatrics 6 2006 7
30. Salinas GD, Robinson CO, Burton BS, et al. Current attitudes and practice patterns of using new and emerging therapies to manage patients with AF: a national assessment of cardiologists and primary care physicians. Poster presented at: the Quality of Care and Outcomes Research 2012 Scientific Sessions (QCOR); May 9-11, 2012; Atlanta, Ga.
31. N.A. Estes III, J.L. Halperin, and H. Calkins ACC/AHA/Physician Consortium 2008 clinical performance measures for adults with nonvalvular atrial fibrillation or atrial flutter: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures and the Physician Consortium for Performance Improvement (Writing Committee to Develop Clinical Performance Measures for Atrial Fibrillation): developed in collaboration with the Heart Rhythm Society J Am Coll Cardiol 51 2008 865 884
32. D.E. Singer, G.W. Albers, and J.E. Dalen Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition) Chest 133 2008 546S 592S
33. A.K. Abdel-Latif, X. Peng, and B.J. Messinger-Rapport Predictors of anticoagulation prescription in nursing home residents with atrial fibrillation J Am Med Dir Assoc 6 2005 128 131
34. T.S. Dharmarajan, S. Varma, and S. Akkaladevi To anticoagulate or not to anticoagulate? A common dilemma for the provider: physicians' opinion poll based on a case study of an older long-term care facility resident with dementia and atrial fibrillation J Am Med Dir Assoc 7 2006 23 28
35. D.A. Lane, and G.Y. Lip Barriers to anticoagulation in patients with atrial fibrillation: changing physician-related factors Stroke 39 2008 7 9
36. D. Pugh, J. Pugh, and G.E. Mead Attitudes of physicians regarding anticoagulation for atrial fibrillation: a systematic review Age Ageing 40 2011 675 683
37. G.Y. Lip, G. Agnelli, and A.A. Thach Oral anticoagulation in atrial fibrillation: a pan-European patient survey Eur J Intern Med 18 2007 202 208
38. S. Connolly, J. Pogue, and R. Hart Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial Fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial Lancet 367 2006 1903 1912
39. J.H. Shin, and Y. Scherer Advantages and disadvantages of using MDS data in nursing research J Gerontol Nurs 35 2009 7 17